19. ライソゾーム病 Lysosomal storage disease Clinical trials / Disease details

臨床試験数 : 854 / 薬物数 : 716 - (DrugBank : 105) / 標的遺伝子数 : 70 - 標的パスウェイ数 : 191

1 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-007482-21-GB (EUCTR)	09/11/2009	17/08/2009	Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study - The FAACET Study	Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria with ACE Inhibitors and ARBS in Patients with Fabry Diseaswe Who Are receiving Farazyme : Tha Farazyme + Arbs + ACE inhibitors Treatments (FAACET) Study: The FAACET Study - The FAACET Study	Fabry disease with proteinuria. MedDRA version: 9.1;Level: LLT;Classification code 10018058;Term: Gene genetic abnormality MedDRA version: 9.1;Classification code 10037032;Term: Proteinuria	Trade Name: perdix Product Name: perdix Trade Name: Zestoretic 10,20 Product Name: ZESTORIC Trade Name: INNOZIDE Product Name: innozide Trade Name: lisinopril Product Name: lisinopril Trade Name: zestril Product Name: zestril Trade Name: coversyl Product Name: coversyl Trade Name: coversyl PLUS Product Name: coversyl PLUS Trade Name: Accupro Product Name: Accupro Trade Name: Accuretic Product Name: Accuretic Trade Name: lopace Product Name: lopace Trade Name: lopace Product Name: lopace Trade Name: triapin Product Name: triapin & triapin Mite	Salford Royal NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes		Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom